Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01106235 · ClinicalTrials.gov registry record · Phase 1
Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01106235 is a Phase 1 study that was terminated before completion, run by Fred Hutchinson Cancer Center. The registered enrollment target is 12 participants.
The verdict
NCT01106235, a Phase 1 study, was terminated before completion, sponsored by Fred Hutchinson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
RATIONALE: Aldesleukin may stimulate lymphocytes to kill melanoma cells. Treating lymphocytes with interleukin-21 in the laboratory may help the lymphocytes kill more tumor cells when they are put back in the body. Giving therapeutic autologous lymphocytes together with cyclophosphamide and aldesleukin may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of giving therapeutic autologous lymphocytes together with cyclophosphamide and aldesleukin in treating patients with metastatic melanoma
Interventions
- DRUG cyclophosphamide
- PROCEDURE biopsy
- BIOLOGICAL therapeutic autologous lymphocytes
- BIOLOGICAL aldesleukin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01106235
The ClinicalTrials.gov registry entry for NCT01106235 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which cyclophosphamide is the first listed.
NCT01106235 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01106235 about?
NCT01106235 is a clinical study titled "Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma". RATIONALE: Aldesleukin may stimulate lymphocytes to kill melanoma cells. Treating lymphocytes with interleukin-21 in the laboratory may help the lymphocytes kill more tumor cells when they are put back in the body. Giving therapeutic autologous lymphocytes together with cyclophosphamide and aldesleu...
What is the current status of trial NCT01106235?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2010-04.
What interventions are being tested in trial NCT01106235?
The interventions under investigation include: cyclophosphamide (DRUG), biopsy (PROCEDURE), therapeutic autologous lymphocytes (BIOLOGICAL), aldesleukin (BIOLOGICAL).
Who is sponsoring clinical trial NCT01106235?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.